8 unknown. 8 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 8 |
| Phase 1 | 4 | Unknown 4 |
| Phase 3 | 1 | Unknown 1 |
Follow Efficacy: new trials by email Literature Review of Efficacy trials Research Report on Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer Tirolizumab+SOX/XELOX, SOX/XELOX - Locally Advanced Gastric Carcinoma, HER2 Negative | Phase 2 | Unknown | Lin Chen | 80 | 2023-10-01 | 2024-02-29 |
| A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab Oral sotorasib + IV Panitumumab - Efficacy | Phase 2 | Unknown | Korea University Anam Hospital | 24 | 2023-07-03 | 2023-08-15 |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors Cadonilimab, Stereotactic body radiotherapy - Advanced Solid Tumor, Stereotactic Body Radiotherapy | Phase 1 / Phase 2 | Unknown | Peking University Third Hospital | 60 | 2023-06-21 | 2023-06-23 |
| Is Local Injection of Mesenchymal Stem Cells After Endoscopic Dilation Safe and Does it Improve the Outcome of Intestinal Stricture in Patients With Crohn's Disease? Mesenchymal Stem Cells, Comparative placebo - Safety Issues, Efficacy | Phase 2 | Unknown | Centre Hospitalier Universitaire de Liege | 50 | 2023-06-06 | 2024-03-19 |
| A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB Hepenofovir Fumarate Tablets - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 48 | 2022-11-10 | 2023-11-08 |
| PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer PD-L1 inhibitor - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2022-04-01 | 2022-04-13 |
| Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma Sintilimab 200mg+MB07133 600mg - Safety Issues, Efficacy | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 39 | 2022-01-18 | 2023-11-21 |
| Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients Advixa (Adalimumab) - Pharmacokinetics, Safety | Phase 2 / Phase 3 | Unknown | Institute for Developing Science and Health Initiatives, Bangladesh | 200 | 2021-06-02 | 2022-07-07 |
Arthritis, Rheumatoid (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Arthritis (1) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Immune System Diseases (1) · Joint Diseases (1) · Musculoskeletal Diseases (1) · Rheumatic Diseases (1) · Skin and Connective Tissue Diseases (1)
4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (1) · Adalimumab (1) · Immune Checkpoint Inhibitors (1) · Panitumumab (1) · Radiosurgery (1) · sintilimab (1) · sotorasib (1)
Xi'an Xintong Pharmaceutical Research Co.,Ltd. (2) · Centre Hospitalier Universitaire de Liege (1) · Institute for Developing Science and Health Initiatives, Bangladesh (1) · Korea University Anam Hospital (1) · Lin Chen (1) · Peking University Third Hospital (1) · The Affiliated Hospital of Qingdao University (1)
China (4) · Bangladesh (1) · Belgium (1) · South Korea (1)
Hongqing Zhuang, M.D. (1) · Xiaochun Zhang, Prof (1) · Zannat Kawser, M.Phil. (1)